Fact-checked by Grok 2 weeks ago

Jet injector

A jet injector is a needle-free that delivers liquid medication, such as or insulin, by propelling a high-pressure stream of the fluid through a narrow to penetrate and deposit the substance into underlying tissues. Invented in during the 1860s, jet injectors remained experimental until the mid-20th century, when they were adapted for efficient mass vaccinations, including the World Health Organization's global eradication campaign starting in 1967, where devices like the "peace gun" enabled the rapid administration of tens of millions of doses without needles. These devices offer advantages such as eliminating risks, standardizing dose delivery, and facilitating high-volume immunizations, making them particularly valuable in settings and for patients with needle phobia. However, early multi-use jet injectors faced significant challenges, including potential transmission of bloodborne pathogens like and due to incomplete sterilization between uses, which contributed to their decline in routine clinical practice by the . Modern iterations, featuring disposable nozzles and improved safety mechanisms, have renewed their application in areas like care for insulin delivery and programs, with ongoing addressing , drug compatibility, and cost barriers to broader adoption. As of 2025, advancements such as Crossject's ZENEO auto-injector are progressing for emergency drug delivery like epinephrine, backed by partnerships with regulatory bodies and the .

Mechanism and design

Operating principles

Jet injection is a needle-free method that employs a high-pressure stream of liquid medication to penetrate and deposit the substance into targeted layers, such as subcutaneous or intramuscular regions. This technique creates a temporary micro-hole in without the use of traditional , relying instead on the of the fluid jet to breach the dermal barrier and facilitate absorption. The process begins with the loaded into a pressurized chamber, where it is then propelled through a narrow at velocities typically ranging from 100 to 200 m/s. The is usually 0.1 to 0.15 mm, and the system generates pressures up to 27,500 kPa (approximately 4,000 ) to achieve sufficient for penetration. Injection volumes commonly fall between 0.5 and 1.5 , with the entire delivery occurring in fractions of a second: an initial high-pressure phase pierces the skin, followed by dispersion of the into the . Fundamentally, the operating principles draw on , particularly , which governs the acceleration of the liquid as it exits the , converting energy into to form a coherent, high-velocity . Penetration into the tissue occurs via momentum transfer from the jet to the skin layers, where the force exerted—qualitatively understood as the product of and the orifice area—determines the jet's ability to displace and enter biological barriers without fragmentation. Key factors influencing depth and efficacy include the orifice size, which affects jet coherence and initial penetration force; the of the medication, as higher can reduce jet and limit depth; and the injected volume, which impacts dispersion patterns. By adjusting pressure and nozzle design, jet injectors can target varying layers: lower pressures for epidermal or dermal , and higher pressures for subcutaneous or intramuscular deposition, enabling precise control over the site of action.

Key components

A jet injector consists of several core physical and functional components that work together to generate and deliver a high-velocity stream for subcutaneous or intramuscular administration. These include a reservoir, a precision , a power source to propel the , a trigger mechanism for activation, and integrated safety features. Materials are selected for sterility, durability, and , with designs often incorporating disposable elements to maintain hygiene. The , or drug chamber, holds the in volumes typically ranging from 0.05 to 3 mL, often constructed from sterile to ensure containment and prevent during storage and delivery. This chamber interfaces directly with the injector's propulsion system, allowing for precise dosing without the need for . In reusable models, the may be refillable, while disposable variants use pre-filled cartridges or ampoules for single-use . The serves as the critical exit point for the medication, featuring a small with a of 0.1 to 0.3 to create the fine, high-speed jet that penetrates the skin. Materials such as or are commonly used for the due to their hardness and resistance to wear under , ensuring consistent jet formation over multiple uses. For example, nozzles with orifices around 0.127 have been employed in delivery systems to achieve depths of 2 to 5.5 . Power sources vary by design but generally provide the needed to accelerate the to velocities of about 100 m/s, generating s up to 4000 (approximately 27.6 ) within the chamber. Common options include compressed gas (e.g., CO2 or cartridges), spring-loaded s, or battery-powered actuators, each building and releasing to drive the fluid through the . The enables controlled activation, either manually via a or that releases stored from the power source, or automatically in advanced electronic models. This component ensures the buildup and sudden release occur in a fraction of a second, typically 0.1 seconds, for efficient injection. Safety features are integral to modern jet injectors, including pressure regulators to maintain consistent output and prevent over-pressurization, as well as auto-disable mechanisms that render the device inoperable after a single use to reduce cross-contamination risks. Dual safety systems, such as locking triggers and visual indicators for readiness, further enhance user safety and device reliability. Overall, the injector's body and internal parts are made from biocompatible materials like sterile plastics for lightweight construction and corrosion resistance, with metallic elements (e.g., or aluminum) used for durable components such as the and pistons. Disposable aspects, including single-use ampoules or syringes, are emphasized in contemporary designs to promote , contrasting with earlier reusable models that required thorough sterilization.

History

Early invention and development

The earliest documented concept for a jet injector emerged in 1866, when surgeon developed the Appareil pour l'aquapuncture, a device that utilized to propel a fine stream of liquid through a small for subcutaneous delivery and . This marked the initial adaptation of high-pressure for medical injection, though it remained largely experimental and was not widely adopted due to technological limitations of the era. Nearly seven decades later, in 1935, mechanical engineer Arnold K. Sutermeister filed a for a high-pressure injection device, inspired by observations of industrial cleaning tools where fluid jets under pressure could penetrate without mechanical aid. Sutermeister's design aimed to apply this principle to hypodermic delivery, using a pressurized reservoir to force liquid through a narrow at velocities sufficient for penetration, though the was not granted until 1954 amid ongoing refinements. A significant advancement occurred in 1947 with the introduction of the by anesthesiologist Robert A. Hingson and pediatrician James G. Hughes, who conducted the first clinical evaluations of a practical compressed-air-powered jet injector for painless drug administration. Their device, based on earlier concepts like Marshall Lockhart's prototype, delivered precise doses of anesthetics and other medications via a high-velocity liquid stream, demonstrating reduced patient anxiety and faster injection times in trials involving over 100 patients. In the , engineer Aaron Ismach further innovated with -driven mechanisms, patenting designs that used a spring-loaded to generate consistent high pressure, prioritizing pain minimization and rapid delivery for broader clinical use. Ismach's contributions, including foot-pedal variants for field applications, addressed portability issues in earlier air-compressed models while enhancing speed for potential mass treatments. Despite these progresses, pre-1960s jet injectors encountered key challenges, such as inconsistent penetration depths resulting from variations in type and stability, alongside medication waste from incomplete dose delivery or . These issues stemmed from rudimentary control and designs, limiting reliability until subsequent engineering improvements.

Adoption in mass immunizations

In 1959, U.S. military physicians Abram Benenson and Ismach developed the Ped-O-Jet at the Army Institute of Research specifically for rapid vaccinations in large-scale programs. This device utilized to propel medication through the skin without needles, enabling efficient delivery in high-volume military settings. Early designs like the from the 1940s influenced these military models by demonstrating the feasibility of pressure-based injection for insulin and other therapeutics. By 1961, the U.S. Army adopted the Ped-O-Jet for widespread immunizations, including , , and vaccines, particularly during the era when troops required quick protection against tropical diseases. The system allowed administration of up to 1,000 doses per hour, with each dose taking approximately 10-15 seconds including positioning and delivery, far surpassing traditional needle methods in speed for mass processing of recruits. Between 1963 and 1980, jet injectors administered an estimated 20 to 40 million doses to U.S. , contributing to over 100 million total injections when including programs. In the 1960s through the 1980s, the (WHO) and Centers for Disease Control and Prevention (CDC) integrated jet injectors into global public health campaigns, notably for eradication and routine vaccinations in developing countries where access to sterile needles was limited. These efforts leveraged the injectors' advantages in mass settings, such as reduced needle phobia among populations, delivery times of 10-15 seconds per dose, and overall cost savings through minimized material use and faster throughput—enabling thousands of immunizations daily by small teams. The program alone utilized jet injectors for 50 to 100 million doses worldwide, accelerating eradication in regions like and .

Decline and regulatory scrutiny

The decline of jet injectors began in the 1980s amid growing evidence of their potential for transmitting bloodborne pathogens through multi-use devices. A notable incident occurred between 1984 and 1985 at a weight reduction clinic in , where 57 out of 239 patients who received injections via a multi-use jet injector developed acute infection, highlighting risks from inadequate sterilization between uses. This outbreak, linked to retrograde blood flow contaminating the injector's and internal components, prompted investigations by the Centers for Disease Control and Prevention (CDC) and underscored the device's vulnerability to cross-contamination in clinical settings. By the mid-1990s, research further quantified these risks, with studies demonstrating cross-contamination rates of 1-6% in multi-use nozzle jet injectors during simulated or actual use, primarily due to blood and tissue residue persisting despite surface disinfection. In response, the (WHO) recommended against the routine use of jet injectors in mass immunization campaigns, favoring single-use needles to minimize transmission of , hepatitis C, and . This policy shift reflected broader concerns over iatrogenic infections in resource-limited settings where sterilization protocols were often challenging to enforce. The U.S. Department of Defense () formalized these concerns in 1997 by halting the use of jet injectors for military immunizations, citing documented risks of and transmission based on outbreak data and laboratory simulations. During the , manufacturers attempted redesigns incorporating disposable cartridges and improved barriers to reduce , but these efforts failed to reverse the overall decline, as safer, cost-effective alternatives like auto-disable syringes gained preference in global health programs.

Types

Traditional multi-use injectors

Traditional multi-use jet injectors were reusable devices designed for high-volume administration of medications, particularly in mass immunization campaigns, featuring shared nozzles and chambers that required cleaning and sterilization between uses. These injectors propelled liquid medication through a narrow at high velocity to penetrate without , typically delivering intradermal, subcutaneous, or intramuscular doses. Key examples include the Ped-O-Jet and Dermojet, which relied on mechanical mechanisms to generate the necessary for jet formation. The Ped-O-Jet, developed in the , utilized a hydraulic foot as its power source, allowing operators to build manually for repeated firings without external or gas. In contrast, the Dermojet employed a spring-loaded mechanism, achieving pressures around 1,420 psi to eject fixed 0.1 doses from a 4 reservoir. Other variants, such as the Med-E-Jet, incorporated compressed CO2 canisters for portable, gas-powered operation, enabling consistent propulsion in field settings. These designs emphasized durability for multiple uses, with nozzles often autoclaved at 134°C for 18 minutes between patients to mitigate contamination risks. Early U.S. models, standardized by the in 1961 as multi-use nozzle jet injectors (MUNJIs), exemplified these features for rapid troop immunizations, while the variant from the late 1940s focused on self-administration of insulin using a compact, mechanically simple design. These injectors were prevalent in and environments from the through the , supporting drives where they could deliver 50-100 doses per setup, depending on reservoir capacity and dose volume. Despite their , traditional multi-use injectors had inherent limitations, including higher potential for cross-contamination due to incomplete sterilization of shared components, as residual fluids could persist on nozzles. from repeated use often led to inconsistent dosing, with jets penetrating deeper than intended, causing variable delivery depths, , or . These issues contributed to their eventual decline in favor of safer alternatives.

Modern disposable and single-use designs

Modern disposable and single-use jet injectors represent a significant evolution in needle-free technology, designed primarily to eliminate cross-contamination risks associated with reusable components while enhancing user safety and convenience. These devices are broadly classified into two main types: Protector Cap Needle-Free Injectors (PCNFI), which employ disposable protective caps that shield the reusable and are discarded after each use to prevent transfer, and Disposable-Cartridge Jet Injectors (DCJI), which utilize pre-filled, single-use cartridges containing the to ensure sterility throughout the injection process. PCNFIs, such as early models like the HSI-500, maintain a reusable mechanism but isolate interface via the cap, while DCJIs fully segregate the from the body, allowing for straightforward disposal after administration. Powering these injectors are typically spring-loaded or compressed gas mechanisms, which generate the high-pressure jet required for skin penetration, often achieving velocities between 100 and 300 m/s to propel the liquid stream effectively without needles. Some advanced designs incorporate battery-powered electromagnetic actuators, such as linear Lorentz-force motors, for more precise control over jet dynamics and portability in self-administration scenarios. Key commercial examples include the PharmaJet Stratis, a DCJI approved by the FDA in 2014 for delivering 0.5 mL doses of inactivated influenza vaccine, demonstrating reliable intradermal and intramuscular performance. In the U.S., the Injex (INJEX 30) serves as a spring-powered option for insulin delivery, while the InsuJet, introduced in the UK around 2015, offers a portable system for subcutaneous injections using disposable nozzles. Additionally, the ZomaJet, acquired by Ferring Pharmaceuticals in 2017, is tailored for growth hormone administration via pre-filled cartridges, supporting doses up to 10 mg/mL. Recent advancements in these designs focus on improving usability and patient comfort, including auto-retracting nozzles that minimize post-injection residue and , alongside precise dosing capabilities ranging from 0.1 mL for intradermal applications to 1 mL for subcutaneous or intramuscular routes. Optimized orifice sizes, often reduced to micrometer scales, contribute to lower pain levels by creating finer jets that penetrate more gently compared to earlier models. These features, combined with ergonomic portability, have driven growing adoption for self-administration, particularly in therapies. Market analyses project the jet injector sector to expand at a (CAGR) of approximately 7.9% from 2025, reaching $4.2 billion by 2032, fueled by demand for safe, user-friendly alternatives in home-based care.

Applications

Vaccination and immunization

Jet injectors played a significant role in mass campaigns during the and , particularly in the early phases of the World Health Organization's smallpox eradication program, where devices like the Ped-O-Jet administered tens of millions of doses across and . This technology enabled rapid of large populations, with one device capable of delivering up to 1,000 doses per hour, facilitating the delivery of over 100 million vaccinations globally in eradication efforts by the 1980s. Their use extended to other programs, including initiatives in the , where they supported efficient deployment in high-volume settings. Jet injectors are compatible with inactivated vaccines, such as those for and , producing immune responses equivalent to traditional needle methods. For instance, the PharmaJet Stratis device received FDA approval in 2014 for delivering the AFLURIA to individuals aged 18-64, demonstrating non-inferior and safety compared to needle-and-syringe administration. However, live attenuated vaccines present challenges due to potential stability issues from the high shear forces generated during , which can affect viral viability, though responses remain generally comparable when stability is maintained. In vaccination contexts, jet injectors offer benefits like reduced pain—reported as less intense and frequent than with fine-gauge needles—and faster administration rates, making them suitable for outbreak responses. Studies indicate they elicit similar seroconversion rates for vaccines while minimizing and enabling quicker mass deployment, as seen in potential applications where rapid immunization is critical. Limitations include incompatibility with highly viscous formulations, such as certain lipid nanoparticle-based COVID-19 vaccines, where the required pressure exceeds standard jet injector capabilities, potentially leading to inconsistent delivery. Despite advancements in disposable designs, these constraints restrict their use to lower-viscosity vaccines in modern immunization programs.

Therapeutic drug delivery

Jet injectors play a key role in therapeutic drug delivery for chronic conditions, enabling needle-free subcutaneous administration of medications in clinical and home environments. For diabetes management, the InsuJet device delivers insulin rapidly and painlessly, promoting faster absorption and better glycemic control compared to traditional needles. In growth hormone therapy, the Zomajet system administers somatropin formulations like ZOMACTON, offering a convenient option for pediatric and adult patients requiring daily injections. For pain management in arthritis and cancer, devices such as the J-Tip provide virtually painless delivery of local anesthetics or analgesics, reducing procedural discomfort during treatments. Emerging applications extend to , where needle-free jet injectors facilitate superficial delivery of , shortening procedure times from 20-25 minutes to about 5 minutes while enhancing patient comfort and safety, as detailed in a 2025 review. In veterinary practice, these injectors are employed for delivering steroids and to animals, allowing efficient administration to large groups with minimal handling stress. Jet injectors are designed for precise subcutaneous delivery of volumes up to 0.5 , making them ideal for self-use by patients managing chronic conditions like or growth deficiencies. Modern disposable designs support this home-based application, simplifying routine . Key advantages include a lower incidence of needle-stick injuries, safeguarding healthcare workers during administration, and more consistent absorption rates that support predictable therapeutic outcomes. The increasing global prevalence of , affecting 589 million adults (aged 20-79) as of 2025, is fueling demand for jet injectors in therapeutic delivery, with the needle-free injector market anticipated to expand at a (CAGR) of 12.08% from 2025 to 2032.

Benefits and limitations

Advantages over hypodermic needles

Jet injectors offer reduced compared to hypodermic needles due to the absence of needle penetration and the rapid, diffuse delivery of through a high-pressure stream. Studies have demonstrated significantly lower scores during procedures such as injections and arterial cannulation with jet injectors, with one trial reporting mean scores of 3 versus 23 on a 0-100 visual analog scale for needle infiltration. Another investigation found that 76.7% of participants experienced no following jet injection, compared to higher discomfort rates with conventional needles. These devices enhance user safety by eliminating needle phobia and preventing sharps injuries among healthcare workers. Jet injectors are particularly beneficial for patients with needle aversion, providing a viable alternative that minimizes anxiety during injections. By removing the need for needles, they reduce the risk of needlestick injuries, which account for approximately 37% of work-related infections and 39% of infections in healthcare settings, with estimates indicating up to 29% of such injuries are preventable through needle-free methods. Jet injectors improve efficiency in , enabling faster administration—often in fractions of a second—compared to the preparation and injection time required for hypodermic needles. This speed is advantageous in mass campaigns, where historical use allowed up to 1,000 injections per hour, simplifying and reducing overall procedure time. Additionally, they eliminate needle disposal waste, streamlining operations without generating sharps hazards. In terms of accessibility, jet injectors are well-suited for resource-limited settings, children, and the elderly, as their needle-free design facilitates easier use in field conditions or for individuals sensitive to traditional injections. During house-to-house campaigns, 91% of vaccinators highlighted the absence of sharps disposal as a key benefit, enhancing practicality in low-resource environments. Their operational simplicity supports broader efforts without requiring advanced training. Physiologically, jet injectors may improve for certain drugs through even dispersion in s, leading to more uniform absorption than the localized delivery of hypodermic needles. This results in faster onset and potentially enhanced efficacy, as observed with insulin where accelerated absorption improved glycemic control. In applications, the broader distribution can boost compared to needle-based methods.

Operational and practical challenges

Jet injectors present several operational and practical challenges that limit their widespread adoption in clinical settings. One primary hurdle is the high upfront cost of the devices themselves, which typically range from $200 to $700 per unit, significantly exceeding the cost of traditional hypodermic needles at approximately $0.25 each. Additionally, while disposable cartridges or nozzles for jet injectors cost around $0.12 per use, the overall expense per dose remains higher than the $0.10 for disposable syringes, making them less economical for large-scale programs. These costs can strain budgets in resource-limited environments, despite potential long-term savings in high-volume scenarios. Training requirements add another layer of complexity, as operators must learn precise techniques for maintaining skin contact and applying consistent pressure to ensure effective delivery without causing bruising or incomplete injection. Inadequate training can lead to variability in outcomes, with studies noting the need for specialized instruction to optimize performance. This demand for skilled personnel contrasts with the simplicity of syringe use and can hinder deployment in understaffed facilities. Medication constraints further restrict applicability, as jet injectors may face challenges with highly viscous fluids (e.g., above 20-30 ), as increased resistance can reduce jet velocity and penetration, though some devices can handle up to 87 with adjustments. They are also limited to small volumes, typically under 2 , beyond which dispersion becomes uneven and multiple injections may be required. Moreover, the high forces generated during propulsion can potentially degrade sensitive biologics like proteins, although exposure duration is shorter than in needle-based systems. Maintenance of reusable jet injectors involves rigorous sterilization protocols, such as autoclaving, to prevent between uses, which adds time and logistical burdens compared to single-use syringes. can vary significantly from 1 to 10 mm depending on factors like pressure settings, skin type, and device calibration, necessitating adjustments that may not always be feasible in field conditions. Accessibility remains a key challenge, particularly in low-income regions, where jet injectors are bulkier and less readily available following the World Health Organization's shift toward auto-disable syringes in the early to enhance safety. This transition has reduced distribution networks for jet devices, limiting their use in mass campaigns despite their speed advantages in high-volume settings.

Safety and regulatory aspects

Cross-contamination risks

Jet injectors, particularly multi-use designs, pose significant cross-contamination risks due to mechanical and biological factors that can transfer infectious material between patients. These devices propel medication at high velocity through the skin, but the process can lead to the mixing of patient fluids with the injector or subsequent doses, facilitating the spread of bloodborne pathogens such as hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). One primary is splash-back, where the high-velocity impacts , causing or to rebound and contaminate the . This forceful rebound expels , including potential particles, back toward the device, increasing the risk of transfer to the next user. Another , suck-back, occurs when pressure is released after injection, creating a vacuum effect that draws or tissue fluids left on the into the injector's internal components, thereby contaminating the reservoir for future doses. flow contributes further, as injected mixes with subcutaneous and tissue along the injection path and leaks back through the skin puncture, potentially re-entering the and mixing with the next injection. Evidence of transmission includes documented outbreaks of HBV linked to jet injectors. In a 1985 incident at a weight-reduction clinic, 24% (60 of 287 tested) of patients at the clinic developed evidence of recent HBV infection, with 24% among jet injector users versus 0% among those using syringes only; the outbreak ceased after jet injector use was halted. While direct cases of or HCV transmission via jet injectors are not reported, the potential exists due to the transfer of contaminated fluids, with surface swabs from injection sites detecting viral markers in infected subjects. Key risk factors include the use of multi-use nozzles without adequate disinfection between patients, which allows residual or fluids to persist. Studies modeling contamination have demonstrated that jet injectors can transfer significant volumes of —over 10 picoliters per injection—sufficient to transmit HBV, with transfer frequency and volume varying by device design. These risks prompted the U.S. Department of Defense to halt jet injector use for mass vaccinations in due to concerns.

Mitigation measures and approvals

To address cross-contamination risks such as suck-back in jet injectors, modern designs incorporate single-use protective caps or in partially covered nozzle-free injectors (PCNFI), which shield the reusable nozzle from direct and are discarded after each use. Similarly, disposable jet injectors (DCJI) utilize pre-filled, single-use cartridges that eliminate by separating the drug reservoir from the reusable actuation mechanism, ensuring no fluid pathway for between patients. Regulatory protocols emphasize rigorous sterilization for reusable components in multi-use devices, with guidelines recommending autoclaving or chemical disinfection like immersion in 2% for 30 minutes followed by a sterile rinse to achieve sterility assurance levels comparable to hypodermic . The U.S. (FDA) classifies jet injectors as Class II medical devices, requiring premarket notification via the 510(k) pathway to demonstrate substantial equivalence in safety and effectiveness, including validation of no cross-contamination through and human factors testing. Key regulatory approvals include the FDA's 2014 clearance of the PharmaJet Stratis device for intradermal and intramuscular delivery of influenza vaccines, marking a milestone for needle-free vaccination. The Stratis maintains its WHO PQS certification since 2013 for intramuscular and subcutaneous delivery. By 2025, PharmaJet's Tropis intradermal system has seen expansions including applications for tropical medicine vaccines like polio and tuberculosis screening, and partnerships for DNA-based therapies such as HIV vaccines. In March 2025, the WHO deployed PharmaJet's Tropis needle-free system in global polio eradication efforts, highlighting ongoing regulatory support for safe needle-free technologies in public health. In the European Union, devices like the InsuJet have obtained CE marking under the Medical Device Regulation, certifying compliance for subcutaneous insulin delivery in over 40 countries, with usability for patients aged six and older. Ongoing research focuses on technologies to enhance , such as laser-generated microjets that enable precise, superficial delivery with minimal disruption, as explored in studies since the mid-2010s. A 2025 review affirms the of needle-free jet injectors in , reporting low adverse event rates for intradermal fillers and anesthetics, with reduced pain and infection risks compared to needles when using disposable components. Future prospects include integration of jet injection with smart auto-injectors, as seen in digitally controlled systems like , which connect to cloud platforms for dose tracking and adherence monitoring, potentially expanding home-use applications. The global needle-free injector market, encompassing jet technologies, is projected to reach USD 43.54 billion by 2032, driven by safer disposable designs and regulatory advancements.

References

  1. [1]
    Needleless Injectors for the Administration of Vaccines - NCBI - NIH
    Jul 17, 2020 · A needleless or needle-free jet injector (NFJI) uses a high-pressure stream jet to puncture the skin surface without using a needle. ... NFJIs ...
  2. [2]
    Jet Injector - an overview | ScienceDirect Topics
    Jet injectors (JIs) squirt liquid under high pressure to deliver medication needle-free into targeted tissues.313–318 Invented in France in the 1860s (Fig. 61- ...
  3. [3]
    Jet Automatic Hypodermic Injection Apparatus - Vaccine Gun
    The jet injector, nicknamed "peace gun," was a gun-like device that used a piston to deliver vaccine without needles, and could hold 500+ doses.
  4. [4]
    Needle-Free Jet Injectors and Their Potential Applications in Plastic ...
    The first jet injector was invented in 1860, in France, and works by forcing a stream of liquid through a precision nozzle to create a liquid jet that ...
  5. [5]
    A New Concept of Needle-Free Jet Injector by the Impact Driven ...
    Dec 19, 2016 · ... device called a “jet injector.” This medical device employs a high speed liquid jet to replace the needle in a hypodermic syringe and is ...
  6. [6]
    A clinical, epidemiological and laboratory study on avoiding the risk ...
    Jet injectors may transmit blood-borne infections, such as hepatitis B virus (HBV) and human immunodeficiency virus (HIV).
  7. [7]
    Incremental costs of introducing jet injection technology for delivery ...
    Jan 29, 2011 · Unsafe injections have been linked to around 23 million new hepatitis B, hepatitis C, and HIV infections each year [1], and concern has ...
  8. [8]
    Current status and future prospects of needle-free liquid jet injectors
    Jun 23, 2006 · The origin of jet injections dates back to the late 1800s when a technique known as aquapuncture was reported in the medical literature. This ...
  9. [9]
    A Needle-Free Jet Injection System for Controlled Release ... - NIH
    However, needle-free jet injectors have been around since 1866, when the first jet injector was invented by Galante [72,73].
  10. [10]
    [PDF] Needle free injection technology - An overview
    This review describes needle free injection technology involving the generation of force by using compressed gas upon actuation in order to deliver a drug at ...
  11. [11]
    Current engineering and clinical aspects of needle-free injectors
    Dec 20, 2018 · Needle-free injectors enable non-invasive drug delivery by impregnating biological barriers, and are considered the future of drug delivery.Missing: physics | Show results with:physics
  12. [12]
    [PDF] Liquid Needle Free Injectors: Design and Analysis of Power Sources
    Aug 11, 2022 · The goal of needle free liquid jet injections is to puncture human skin and deliver large macro- molecules, while minimizing damage to the skin ...
  13. [13]
    Alternative vaccine delivery methods - PMC - PubMed Central
    ... nozzle jet injector (Keystone Industries) (see Fig. 61-4,C), showing 0.127 mm diameter orifice bored into inset sapphire. Recessed cone within nozzle ...
  14. [14]
    Needle-free Injection Technology - PharmaJet
    PharmaJet's Needle-free Injection Systems deliver a spring-powered injection in 1/10 of a second by means of a narrow stream of fluid that penetrates the skin.Missing: components | Show results with:components
  15. [15]
    Stratis® IM/SC - Needle-free Injection Device - PharmaJet
    Stratis Needle-free Injection System Components · Injector · Syringe – 0.5 ml · 13mm Vial Adapter · 20mm Filling Adapter · Reset Station.
  16. [16]
    Appareil pour l'Aqua-puncture (1866) - Zdravotnické muzeum NLK
    Apr 2, 2021 · Appareil pour l'Aqua-puncture (1866) ... The oldest jet injector was devised by the French physician Jean Sales Girons (1808-1879) in 1866.
  17. [17]
    US2680439A - High-pressure injection device - Google Patents
    The principal object of the invention is to provide an improved pressure and is ejected through a very fine nozzle so that the substance being injected ...Missing: 1935 | Show results with:1935
  18. [18]
    Becton Dickinson & Co. v. R. P. Scherer Corp. et al, 211 F.2d 835 ...
    The case arises out of the following facts: In 1932 Arnold K. Sutermeister, a mechanical engineer, who had noticed that jets of fluid under high pressure ...
  19. [19]
    Clinical studies with jet injection; a new method of drug administration
    Clinical studies with jet injection; a new method of drug administration. Curr Res Anesth Analg. 1947 Nov-Dec;26(6):221-30. Authors. R A HINGSON, J G HUGHES.Missing: Hypospray Robert James
  20. [20]
    Current trends in needle-free jet injection: an update - PMC - NIH
    May 1, 2018 · The initial driving pressure is set to 140 psi, but it could be increased by increments of 10 psi until a wheal or a tiny blood spot appears on ...
  21. [21]
    [PDF] Colonel James C. Rinaman, MC: Bataan Survivor
    Robert Hingson and Dr. James Hughes. By 1951, the Commission on ... The MUNJI, or “multi-use nozzle jet injector” significantly reduced the time ...
  22. [22]
    [PDF] Immunization to Protect the U.S. Armed Forces - DTIC
    The resulting vaccine strain 17D is still used today for travelers to yellow fever-endemic areas of the world, including deployed military personnel. During ...
  23. [23]
    History of Jet Injection - Needle-Free Injection System - J-Tip
    Jet injection was originally discovered in the 19 th century on accident while using high powered grease guns.
  24. [24]
    2001 FDA Jetgun Hearing - Hepatitis C and Military Veterans
    Apr 21, 2017 · ... 1980 have given about 20 to 40 million injections to military personnel. The global smallpox eradication program, 50 to 100 million. During ...
  25. [25]
    [PDF] CDC and the Smallpox Crusade
    Jet injectors, adapted for the purpose by the U.S. military and CDC in the early 1960s, made possible the immunization of thousands of persons by rela tively ...
  26. [26]
    An Outbreak of Hepatitis B Associated With Jet Injections in a Weight ...
    From January 1984 through November 1985, 31 clinical cases of hepatitis B occurred among attendees of a weight reduction clinic (clinic 1).Missing: Los | Show results with:Los
  27. [27]
    Epidemiologic Notes and Reports Hepatitis B Associated with Jet ...
    On initial analysis of the cohort members, exposure to the jet injectors and HCG were both significantly associated with the development of acute HBV infection.Missing: Los | Show results with:Los
  28. [28]
    Preventing contamination between injections with multiple-use ...
    Mar 4, 2008 · This study aimed to determine the presence of hepatitis B virus (HBV) contamination in post-injection ("next person") samples immediately following injection.
  29. [29]
    Vaccine Administration - CDC
    Jun 18, 2024 · Multiple use jet injectors using the same nozzle for consecutive injections without intervening sterilization were used in mass vaccination ...
  30. [30]
    [PDF] Relationship Between Immunization with Jet Injectors and Hepatitis ...
    Jun 29, 2004 · Since the 1990's, injection drug use has been the principal mode of transmission of HCV. Because of screening procedures, HCV is now only rarely.
  31. [31]
    Comparative Evaluation of Three Jet Injectors for Mass Immunization
    TABLE I. Specifications of Jet Injectors. Specifications. Ped-O-Jet. Med-E-Jet. Medi-jector. Power source. Hydraulic foot pump. Compressed C02. Hand crank.
  32. [32]
    [PDF] The Evaluation of Jet Injection for use in Veterinary Medicine, - DTIC
    the power source, the multiple dose injector was cocked by a hydraulic pump ... components of the jet injector gave the most desirable skin penetration ...Missing: key | Show results with:key
  33. [33]
    The development of the hypospray for parenteral therapy by jet ...
    The development of the hypospray for parenteral therapy by jet injection. Anesthesiology. 1949 Jan;10(1):66-75. doi: 10.1097/00000542-194901000-00008.Missing: 1950s design
  34. [34]
    Technologies to Improve Immunization - PMC - PubMed Central - NIH
    To overcome many of the difficulties of needle and syringe injection, multiuse nozzle jet injectors (MUNJIs) were commonly used in the past for IM and SC ...
  35. [35]
    Preventing contamination between injections with multiple-use ...
    The multidose jet injectors were banned after it became clear that cross contamination with, e.g., hepatitis B could occur in subsequent vaccinees. Current jet ...
  36. [36]
    Incremental Costs of Introducing Jet Injection Technology for ...
    Jun 25, 2007 · Rationale: Disposable cartridge jet injectors (DCJIs) have the potential to increase safety and reduce costs of vaccine delivery.
  37. [37]
    Jet injectors: Perspectives for small volume delivery with lasers
    Laser-based microjet injection allows for superficial delivery of small volumes. Superficial delivery allows for dose-sparing of vaccines.Missing: savings | Show results with:savings
  38. [38]
    (PDF) Jet injectors: Perspectives for small volume delivery with lasers
    Sep 30, 2025 · In this perspective, we will discuss the current status of laser-based jet injectors and contrast their advantages and limitations, as well as their potential ...
  39. [39]
    Needle-free jet injection using real-time controlled linear Lorentz ...
    Needle-free drug delivery by jet injection is achieved by ejecting a liquid drug through a narrow orifice at high pressure, thereby creating a fine ...<|control11|><|separator|>
  40. [40]
    PharmaJet secures FDA approval for jet injection system for flu ...
    Aug 27, 2014 · Colorado-based PharmaJet welcomed a nod from the FDA as the regulator approved the first needle-free delivery system for the inactivated flu vaccine.
  41. [41]
    Insulin Jet Injectors: Use, Risks, Cost, and More - Healthline
    Jun 27, 2017 · While insulin jet injectors don't use a needle, they can still cause trauma to your skin. You may have slight bleeding and bruising at the ...
  42. [42]
    InsuJet.eu
    Already launched in Canada, the UK and in France, InsuJet™ offers needle-free insulin delivery to people with diabetes available in Europe.
  43. [43]
    Ferring strengthens growth hormone franchise Zomacton® through ...
    Oct 10, 2017 · Ferring strengthens growth hormone franchise Zomacton® through acquisition of ZomaJet™ needle-free injector device. Ferring enters agreement ...Missing: jet | Show results with:jet
  44. [44]
    Tropis® ID Jet Injector | Needle-free Injection System - PharmaJet
    Tropis ID System Components · Injector – ID · Syringe – 0.1 ml · Filling Adapter · Left-click and drag for a 360 degree view of each component.
  45. [45]
    US20070055200A1 - Needle-free jet injection drug delivery device
    Mar 8, 2007 · The present invention contemplates that a significant reduction in the nozzle orifice size will result in reduced pain to the patient.
  46. [46]
    Jet Injector 2025 to Grow at 7.9 CAGR with 4204 million Market Size
    Rating 4.8 (1,980) Jun 25, 2025 · The global jet injector market is experiencing robust growth, projected to reach $4.204 billion in 2025 and maintain a Compound Annual Growth ...Missing: $4.2 self-
  47. [47]
    FDA Approves the Use of a Needle-Free Injection Device to
    Sep 16, 2014 · The following is from a release dated August 19, 2014: "PharmaJet® Inc., the developer of a needle-free injection technology to administer ...
  48. [48]
    Immunization without needles | Nature Reviews Immunology
    Oct 20, 2005 · This article focuses on contemporary developments in needle-free methods of immunization, such as liquid-jet injectors, topical application to the skin, oral ...
  49. [49]
    Jet injector effective and efficient for delivering flu vaccine - Healio
    Apr 8, 2019 · “First, it allows for vaccines to be given to people with needle phobia. Second, it allows for quick delivery of vaccines in pandemic settings.Missing: deployment | Show results with:deployment
  50. [50]
    Servo-Tube-Powered Liquid Jet Injector for Drug Delivery Applications
    Jul 8, 2022 · ... COVID-19. Thus, a great emphasis is placed on providing the most ... jet injectors for viscous fluids. IEEE Trans. Biomed. Eng. 2016 ...
  51. [51]
    Needle-Free Jet Injection of Rapid-Acting Insulin Improves Early ...
    Jet injectors deliver insulin at a high velocity (typically >100 m/s) directly across the skin in the subcutaneous tissue and dispense the insulin over a larger ...
  52. [52]
  53. [53]
    Ferring Introduces ZOMA-Jet® 10, a New Needle-Free Delivery ...
    Sep 27, 2018 · ZOMA-Jet 10 is a new completely needle-free delivery option available for children and adults being treated with the growth hormone, ZOMACTON 10mg.
  54. [54]
    Transjecting growth hormone: continuous nightmare or controlled ...
    The current study examined GHT users' perceptions of a new needle-free device (ZomaJet Vision X [10 mg/mL]) with a lower injection volume compared to the ...
  55. [55]
    Virtually Painless The J-Tip - Needle-Free Injection System
    The J-Tip needle free injection creates a virtually pain free experience for the patient and can reduce pain during an IV. By using this method during treatment ...Needleless injection · Needle-Free Injector Simple... · Jet Injection Technology...
  56. [56]
    Needle-Free Jet Injectors and Their Potential Applications in Plastic ...
    Apr 2, 2025 · In conclusion, NFJI are a viable, safe, and potentially more efficacious delivery system compared with traditional needle-syringe techniques for ...
  57. [57]
    Needle-free jet injectors for intradermal vaccination of pigs
    The mechanism of needle-free jet injectors relies on the principle of forcing fluids through a small orifice, generating a high-pressure stream that penetrates ...
  58. [58]
    Jet Injector - an overview | ScienceDirect Topics
    Jet injectors are needle-free devices that propel liquid medication through a nozzle at high pressure, delivering it into tissues.
  59. [59]
    The Absorption of Needle-Free Insulin Aspart Through Jet Injector in ...
    Apr 28, 2022 · Additionally, the use of these jet injectors has been reported to markedly improve and accelerate the absorption of rapid-acting insulin from ...
  60. [60]
    Diabetes Devices Market Size, Share & Growth, 2032
    Global diabetes devices market size is projected to reach USD 48.35 billion by 2032, with a CAGR of 6.2% during the forecast period.
  61. [61]
    Needle-Free Injector Market Size to Hit USD 43.54B by 2032
    Spring-loaded jet injectors held nearly 55.0% market share from 2024. Indeed, their application in vaccine and drug delivery without using needles has increased ...
  62. [62]
    Trigger point injections vs. jet injection in the treatment of myofascial ...
    The jet injector system produced significantly less pain during treatment than conventional trigger point injections and therefore was preferred by most ...Missing: advantages | Show results with:advantages
  63. [63]
    Jet injection of local anesthetic decreases pain of arterial ... - PubMed
    Patients in the Bioject group experienced significantly less pain during lidocaine administration and at the time of arterial cannulation by their own and by an ...Missing: study | Show results with:study
  64. [64]
    A Pilot Open-Label Randomized Study to Evaluate the Safety ... - NIH
    Dec 27, 2024 · IM-NFIS proved to be safe, well tolerated, and highly acceptable for delivering pharmaceuticals compared to conventional needle and syringe injections.
  65. [65]
    Efficacy and safety of needle-free jet injector-assisted intralesional ...
    Mar 8, 2023 · Traditional mechanical jet injectors act with a fixed pressure predetermined by spring size [8]. Innovative electronically controlled pneumatic ...Missing: features | Show results with:features
  66. [66]
    Quantifying the Ergonomic Impact on Healthcare Workers Using a ...
    ... Jet injectors are advantageous over needle injectors by eliminating sharps hazards. The Government Accountability Office estimates 29% preventable sharp ...
  67. [67]
    Prevalence and associated factors of needle stick and sharp injuries ...
    Jan 18, 2024 · For healthcare workers worldwide, the attributable fractions for work-related infections exposed to HBV, HCV, and HIV are 37%, 39%, and 4.4%, ...Missing: jet | Show results with:jet
  68. [68]
    [PDF] Feasibility of jet injector use during inactivated poliovirus vaccine ...
    Sep 22, 2023 · Conclusions: The needle-free jet injector was feasible for use in house-to-house campaigns. Acceptability by vaccinators was low as 81% stated ...
  69. [69]
    Feasibility of jet injector use during inactivated poliovirus vaccine ...
    Jul 3, 2018 · This study showed that jet injectors are feasible for intramuscular administration of vaccines in house to house campaigns. However, there was ...Missing: compatibility | Show results with:compatibility
  70. [70]
    [PDF] The Use of Jet-Injectors in BCG Vaccination*
    In mass vaccination programmes, the jet-injection of vaccine may have considerable operational advantages over the classical techniques. The technical ...<|control11|><|separator|>
  71. [71]
    Improved DNA Vaccine Delivery with Needle-Free Injection Systems
    An important advantage seen in studies using modern NFIS is that the immunogenicity elicited by jet delivery of vaccines may be enhanced compared to traditional ...
  72. [72]
  73. [73]
    A model to assess the infection potential of jet injectors used in mass ...
    All injectors tested transmitted significant (over 10 pl) volumes of blood; the volumes and frequency of contamination varied with injector. The source of the ...
  74. [74]
    Vietnam vets blame 'jet guns' for their hepatitis C
    Feb 17, 2016 · The U.S. military used jet injectors to immunize millions of new recruits and troops heading overseas from the 1950s through the late 1990s.
  75. [75]
    Potential for cross-contamination from use of a needleless injector
    Immersion of the head of the injector in a 2% glutaraldehyde solution for 30 minutes followed by a sterile water rinse and the replacement of the rubber cap ...<|control11|><|separator|>
  76. [76]
  77. [77]
    NuGen M.D. Launches New InsuJetTM Brand Store for Direct ...
    NuGen M.D.'s needle-free injection system for self-administered injections is approved by Health Canada, holds a CE Mark and gives access to safe and ...
  78. [78]
    Portal PRIME: A Digitally Controlled, Cloud-Integrated Jet Injection ...
    Jan 16, 2025 · Portal Instruments' needle-free and digitally controlled jet injection device, dubbed PRIME, represents the next generation of needle-free drug delivery ...Missing: cost constraints